Full Press Release Details
INDIANAPOLIS , July 21, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced it will present findings from more than 25 research studies at the upcoming Alzheimer's Association International Conference ® 2016 (AAIC ® 2016) in Toronto, Canada , July 24 – 28. The data highlight a broad research program that targets beta-amyloid and tau, two known hallmarks of Alzheimer's disease, along with positron emission tomography (PET) imaging diagnostics that allow researchers to estimate both pathologies in the living brain.
"Our current pipeline is shaped by the discoveries we've made over nearly three decades of research and development," said J. Anthony Ware , M.D., senior vice president, product development, Lilly Bio-Medicines. "We recognize the significant burden this devastating illness has on patients, caregivers and our society, and we remain deeply committed to finding ways to disrupt the course of this disease."
Of particular interest are two oral presentations which may inform Lilly's future clinical research in Alzheimer's disease:
Additional studies being presented include:
Solanezumab Data
LY3002813 Data (N3pG)
Florbetapir Data
Flortaucipir [18F] AV-1451 Data
AZD3293/LY3314814 Data (BACE Inhibitor)
LY3202626 Data (BACE Inhibitor)
LY2811376 Data (BACE Inhibitor)
General Alzheimer's Disease Data
About Alzheimer's Disease
Alzheimer's disease is a fatal illness that causes progressive decline in memory and other aspects of cognition. It is the most common form of dementia, accounting for 60 to 80 percent of dementia cases. 1,2 It is estimated that there are nearly 47 million people living with dementia worldwide. 1 The number of people affected by dementia is expected to reach nearly 75 million in 2030 and 132 million in 2050. 1 Estimates vary, but experts suggest that as many as 5.4 million Americans may have Alzheimer's disease. 3
About Amyvid™ (Florbetapir F 18 Injection) 4
Amyvid is a radioactive diagnostic agent for Positron Emission Tomography (PET) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) and other causes of cognitive decline.
A negative Amyvid scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient's cognitive impairment is due to AD. A positive Amyvid scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Amyvid is an adjunct to other diagnostic evaluations.
Limitations of Use:
Amyvid for intravenous use is supplied in 10 mL, 30 mL or 50 mL multidose vials containing 500-1900 MBq/mL Florbetapir F 18
WARNINGS AND PRECAUTIONS
Risk for Image Misinterpretation and Other Errors
MOST COMMON ADVERSE REACTIONS
For more information about florbetapir F 18, please see the Prescribing Information at http://pi.lilly.com/us/amyvid-uspi.pdf .
AM HCP ISI 10JAN2014
About Eli Lilly and Company Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and newsroom.lilly.com/social-channels .
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about investigational treatments and diagnostics for Alzheimer's disease, and reflects Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that future study results will be consistent with study findings to-date, or that these investigational compounds or diagnostics will receive regulatory approvals or prove to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's most recent 10-K and 10-Q filings with the United States Securities and Exchange Commission. Except as may be required by law, Lilly undertakes no duty to update forward-looking statements for events occurring after the date of this release.
1 Alzheimer's Disease International. Dementia statistics. http://www.alz.co.uk/research/statistics . Accessed May 2016 .
2 Alzheimer's Association. What Is Dementia? http://www.alz.org/what-is-dementia.asp . Published January 2016 . Accessed May 2016 .
3 Alzheimer's Association. 2016 Alzheimer's Disease Facts and Figures. Alzheimer's & Dementia . Available at http://www.alz.org/documents_custom/2016-facts-and-figures.pdf . Accessed May 2016 .
4 Amyvid [package insert]. Indianapolis, IN : Lilly USA , LLC; 2014.
| Refer to: | Media – Nicole Hebert; [email protected] ; 317.701.9984 |
| Investors – Phil Johnson; [email protected] ; 317.655.6874 |
SOURCE Eli Lilly and Company